Royalty Pharma Plc

Healthcare · Biotechnology

57.20$ -0.8% vs. previous close Closing price · As of: Oct 2, 2026

Statements

Income Statement

Royalty Pharma Plc (RPRX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 674 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement RPRX
Line item	Q2 15	Q3 15	Q4 15	Q1 16	Q2 16	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	–	–	–	–	–	–	0.0	0.0	0.0	0.0	435	458	464	457	501	511	538	572	573	555	586	576	562	536	573	566	684	538	536	596	568	537	565	594	568	579	609	622	631	674	2,536
Cost of Revenue	–	–	–	–	–	–	0.0	0.0	0.0	0.0	50	72	122	919	88	5.7	5.8	129	292	5.7	138	267	185	106	305	309	119	241	277	77	584	6.0	228	164	127	204	1.3	1.2	1.2	268	272
Gross Profit	–	–	–	–	–	–	0.0	0.0	0.0	0.0	435	458	464	457	501	511	538	572	573	555	586	576	562	536	573	566	684	538	536	596	568	537	565	594	568	579	609	622	629	406	2,267
Research & Development	6.5	5.5	4.8	3.8	3.2	3.2	2.6	2.1	1.1	1.0	23	21	23	16	7.6	5.8	5.1	7.8	2.6	3.1	91	104	101	0.6	26	51	0.5	0.5	51	0.5	0.5	0.5	0.5	0.5	51	301	51	51	40	98	239
Selling, General & Administrative	7.8	6.6	6.3	4.9	4.3	4.2	4.0	5.9	2.0	1.9	24	30	26	23	38	43	51	50	43	45	49	46	52	52	51	73	86	48	57	59	58	55	57	68	111	180	119	164	159	162	604
Total Operating Expenses	–	–	–	–	–	–	0.0	0.0	0.0	0.0	4.0	130	-68	-874	139	102	28	258	344	-190	283	422	342	158	381	1,048	205	289	385	-17	642	268	-170	232	34	369	182	234	-3.1	273	685
Operating Income	–	–	–	–	–	–	-4.0	-5.9	-2.2	-1.8	431	328	532	1,332	361	409	511	314	229	745	303	153	220	378	192	-483	479	249	151	613	-74	270	735	362	534	210	427	388	632	133	1,581
Interest Expense	–	–	–	–	–	–	–	–	–	–	67	69	69	63	54	34	31	38	37	37	44	47	47	47	47	47	47	47	46	47	44	49	67	66	65	69	80	94	94	94	361
Pre-Tax Income	–	–	–	–	–	–	-4.0	-5.9	-2.2	-1.6	396	179	440	1,447	109	602	624	367	159	807	222	54	128	492	220	-610	509	351	122	718	-4.3	194	806	334	433	91	444	356	468	81	1,350
Income Tax Expense	–	–	–	–	–	–	0.0	0.0	0.0	0.0	90	88	92	79	76	160	334	-531	90	366	120	47	168	187	2.6	0.1	168	124	50	223	-9.1	92	262	126	–	60	156	142	173	–	–
Net Income	–	–	–	–	–	–	-4.0	-5.9	-2.2	-1.6	367	152	409	1,420	71	442	291	171	69	441	102	7.9	52	305	143	-456	341	228	72	494	4.8	102	544	208	238	30	288	214	295	18	815
EBITDA	–	–	–	–	–	–	–	–	–	–	470	254	515	1,516	168	642	661	410	202	850	272	106	181	539	267	-563	556	398	168	765	40	243	873	400	499	159	525	451	563	176	1,716

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings